SCHEMBL16101161

SCHEMBL16101161

COC(=O)C1CN(C(=O)OC(C)(C)C)CCN1C1CN(C(c2ccccc2)c2ccccc2)C1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.44
MEN1 O00255 1/20 0.44
CYP3A4 P08684 3/20 0.42
CYP2D6 P10635 3/20 0.42
CYP2C9 P11712 3/20 0.42
CYP2C19 P33261 2/20 0.42
MGLL Q99685 1/20 0.40
ATM Q13315 1/20 0.40
GPR119 Q8TDV5 2/20 0.40
NPC1 O15118 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
MAPK1 P28482 1/20 0.40
HTT P42858 1/20 0.40
RAB9A P51151 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
STS P08842 1/20 0.39
OPRD1 P41143 1/20 0.39
GLS O94925 1/20 0.39
USP30 Q70CQ3 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16117974 0.90 KMT2A (0.46) KMT2AMEN1CYP3A4CYP2D6CYP2C9
SCHEMBL16117972 0.88 KMT2A (0.44) KMT2AMEN1CYP3A4CYP2D6CYP2C9
SCHEMBL16822551 0.86 KMT2A (0.46) KMT2AMEN1CYP3A4CYP2D6CYP2C9
SCHEMBL16117985 0.86 KMT2A (0.46) KMT2AMEN1CYP3A4CYP2D6CYP2C9
SCHEMBL27402995 0.84 GPR119 (0.44) KMT2AMEN1CYP3A4CYP2D6CYP2C9
SCHEMBL30961634 0.84 GPR119 (0.44) KMT2AMEN1CYP3A4CYP2D6CYP2C9
SCHEMBL6840313 0.83 KMT2A (0.44) KMT2AMEN1MGLLGPR119NPC1
SCHEMBL3234860 0.82 ALDH1A1 (0.43) KMT2AMEN1MGLLGPR119NPC1
SCHEMBL694333 0.81 KMT2A (0.50) KMT2AMEN1CYP3A4CYP2D6CYP2C9
SCHEMBL5136397 0.78 KMT2A (0.46) KMT2AMEN1CYP3A4CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3401314-B1 COVALENT INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-11-08 EP disclosed
EP-3401314-B1 COVALENT INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-11-08 EP disclosed
US-10919850-B2 Covalent inhibitors of KRas G12C ARAXES PHARMA LLC (US) 2021-02-16 US disclosed
US-10919850-B2 Covalent inhibitors of KRas G12C ARAXES PHARMA LLC (US) 2021-02-16 US disclosed
US-20190262342-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER ARAXES PHARMA LLC 2019-08-29 US disclosed
US-10273207-B2 Covalent inhibitors of kras G12C ARAXES PHARMA LLC (US) 2019-04-30 US disclosed
US-10273207-B2 Covalent inhibitors of kras G12C ARAXES PHARMA LLC (US) 2019-04-30 US disclosed
EP-3401314-A1 COVALENT INHIBITORS OF KRAS G12C Araxes Pharma LLC (US) 2018-11-14 EP disclosed
US-10111874-B2 Combination therapies for treatment of cancer ARAXES PHARMA LLC (US) 2018-10-30 US disclosed
US-20180162812-A1 COVALENT INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2018-06-14 US disclosed
US-20160166571-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER ARAXES PHARMA LLC 2016-06-16 US disclosed
US-20160159738-A1 COVALENT INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2016-06-09 US disclosed
US-20160159738-A1 COVALENT INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2016-06-09 US disclosed
EP-2970121-A1 COVALENT INHIBITORS OF KRAS G12C Araxes Pharma LLC (US) 2016-01-20 EP disclosed
US-9227978-B2 Covalent inhibitors of Kras G12C ARAXES PHARMA LLC (US) 2016-01-05 US disclosed
US-9227978-B2 Covalent inhibitors of Kras G12C ARAXES PHARMA LLC (US) 2016-01-05 US disclosed
WO-2014152588-A1 COVALENT INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2014-09-25 WO disclosed
WO-2014152588-A1 COVALENT INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2014-09-25 WO disclosed
US-20140288045-A1 COVALENT INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2014-09-25 US disclosed
US-20140288045-A1 COVALENT INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2014-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140288045-A1 COVALENT INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS KMT2A 535/4885MEN1 2271/4885CYP3A4 4548/4885
US-20160159738-A1 COVALENT INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS KMT2A 535/4885MEN1 2271/4885CYP3A4 4548/4885
US-20180162812-A1 COVALENT INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS KMT2A 535/4885MEN1 2271/4885CYP3A4 4548/4885
US-10111874-B2 Combination therapies for treatment of cancer KRAS, TP53, HRAS KMT2A 1502/4885MEN1 872/4885CYP3A4 4654/4885
US-20190262342-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER KRAS, TP53, HRAS KMT2A 1502/4885MEN1 872/4885CYP3A4 4654/4885
US-10919850-B2 Covalent inhibitors of KRas G12C KRAS, NRAS, HRAS KMT2A 535/4885MEN1 2271/4885CYP3A4 4548/4885
US-20160166571-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER KRAS, TP53, HRAS KMT2A 1502/4885MEN1 872/4885CYP3A4 4654/4885
US-10273207-B2 Covalent inhibitors of kras G12C KRAS, NRAS, HRAS KMT2A 535/4885MEN1 2271/4885CYP3A4 4548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.